GlaxoSmithKline plc Stumbles But It’s Still A Buy

Drug setbacks highlight GlaxoSmithKline plc’s (LON:GSK) robustness

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Drug-maker GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has announced its third setback in almost as many days with news of failed drugs trials. The shares are down 3% since the start of the week.  But that’s quite a muted response to three disappointments in GSK’s late-stage pipeline, which to my mind demonstrates the company’s robustness. I doubt rival AstraZeneca (LSE: AZN) (NYSE: AZN.US) could meet a triple failure with such equanimity.

Bad news comes in threes

On Wednesday GSK announced it had halted the last-stage trials of lung-cancer vaccine MAGE-A3. On Monday it withdrew an application for approval of an ovarian cancer drug called Votrient after disappointing Phase III studies. The day before it had released details of its unsuccessful trials of heart disease therapy darapladib.

gskThis is not the end of the road for these drugs: trials will continue on their efficacy in different clinical situations. But it is a significant setback in GSK’s pipeline. GSK acquired darapladib with its $3bn acquisition of US biotech firm Human Genome Sciences in 2012 and it was considered one of its leading prospects. MAGE-A3 is an immunotherapy treatment which stimulates the body’s own immune system to treat cancer.  It’s a field where GSK has been lagging — and still is.

People attach significance to events that come in threes: buses, accidents, bad news, profit warnings, whatever. Perhaps it’s because two things happening together isn’t unusual – just a ‘coincidence’ – whilst the laws of randomness make four events a rarer occurrence. My hunch is that similar triple disappointments at Astra would have sent its stock plunging on talk of its business model failing. AstraZeneca’s share price is supported by faith in the company delivering on its ambitious pipeline, a balloon that could easily burst.

Less risky than Astra

That, in a nutshell, is why I hold GSK but no longer hold Astra. GSK has lower downside risk. It has largely overcome the patent cliff. Turnover has stabilised, with two new asthma and respiratory drugs hopefully replacing sales from the company’s blockbuster product Advair. In contrast even Astra’s own CEO doesn’t expect to see sales recovering until 2017: the longer time frame means more uncertainty.

GSK also has two business lines less susceptible to the uncertainties of scientific discovery. Conventional vaccines and consumer healthcare, such as over-the-counter medicines, make up a third of turnover.

GSK has the largest vaccines business in the world, and whilst it’s managed alongside the pharmaceuticals business it doesn’t require the same massive upfront R&D investment. The consumer healthcare market is driven by ageing populations in the developed world and increasing wealth in emerging markets, just like the pharmaceuticals business is. But its characteristics are more like a consumer goods company than a drugs company.

Cheaper than Astra

Remarkably, in the light of its lower risk, GSK is actually now cheaper than Astra: on a forward PE of 14.4 against 15.3, and yielding 4.9% against 4.5%. It could be a good time to prescribe a dose of GSK shares to inoculate against pension poverty!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony owns shares in GSK but no other shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

 

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »